Methylphenidate (Ritaline, Concerta, Quasym, Medikinet) — the detail without marketing

Why this page exists

Open a search engine on “Ritalin adult” and you land on two kinds of content: enthusiastic testimonials (“it changed my life”) and alarmist articles (“hard drug in pill form”). Between the two, there’s the scientific literature — long, nuanced, and rarely summarised honestly.

This page does the honest summary. It won’t tell you whether you should take methylphenidate — that’s the conversation with your psychiatrist. It’ll give you what you need to have that conversation from an informed position.

What it is, concretely

Methylphenidate is the active ingredient. In France, it’s marketed under several names ^[11] :

Brand	Formulation	Approximate duration
Ritaline	Immediate release (IR), tablet	3-4 hours
Ritaline LP	Extended release, capsule	6-8 hours
Concerta LP	Extended-release OROS, tablet	10-12 hours
Quasym LP	Extended release, capsule	8 hours
Medikinet LP	Extended release, capsule	8 hours
Methylphenidate Arrow, Mylan, Biogaran, etc.	Generics	Equivalent

Durations are indicative — individual response varies hugely.

How it acts in the brain

Plainly: methylphenidate blocks the reuptake (the recycling) of two neurotransmitters, dopamine and noradrenaline, in the synapses ^[6] . It doesn’t add dopamine — it lets the dopamine already produced circulate longer.

At therapeutic doses, it blocks roughly 60-70% of dopamine transporters in the striatum and 70-80% of noradrenaline transporters in the frontal cortex. That’s why it improves attention (frontal cortex) and motivation / initiation (striatum).

What the evidence says — efficacy

The big meta-analyses

In psychiatry, we don’t judge a treatment on an isolated trial. We look at what the synthesis of dozens of trials says.

Cortese 2018 (Lancet Psychiatry)

The reference network meta-analysis ^[5] . 133 randomised double-blind trials. Adult conclusion: amphetamines and methylphenidate are superior to placebo. Methylphenidate seen as the most favourable efficacy/tolerability balance in children, amphetamines (unavailable in France for a long time) in adults.

Gosling, Cortese et al. 2025 (BMJ)

Umbrella review of 221 meta-analyses ^[4] . For adults: methylphenidate, atomoxetine, CBT (and amphetamines in high-quality studies) have at least moderate-certainty evidence of efficacy on ADHD symptoms with a medium effect size. Methylphenidate has tolerability similar to placebo (which isn’t true for amphetamines, which are less well tolerated).

Farhat 2024 (JAMA Psychiatry)

Dose-response meta-analysis ^[9] on adults. Off-label doses (above recommendations) provide a small additional symptom reduction, probably not clinically relevant, and increase dropouts due to adverse effects. Conclusion: staying within the authorised range is the reasonable rule.

What that means in practice

Side effects — no sugar-coating

The most frequently encountered adverse effects (≥ 1/10 patients) are nervousness, insomnia, decreased appetite and headaches ^[11] .

Common (≥ 1/10 or ≥ 1/100)

• Decreased appetite — often early in treatment, fades after a few weeks for many. Impact on weight to be monitored.
• Sleep-onset insomnia — especially if taken late. Morning dosing + never after 3-4 p.m. depending on extended-release formulation.
• Headaches — often transient.
• Dry mouth, mild nausea.
• Nervousness, mild anxiety, irritability.
• Mild tachycardia and blood-pressure change — average increase of 5-10 bpm in heart rate and 2-4 mmHg in systolic blood pressure ^[7] .

Less common but worth knowing

• Reduced libido, sexual dysfunction.
• Bruxism (teeth grinding).
• Tics — can appear or worsen in predisposed people.
• End-of-dose rebound: sudden return of symptoms + transient irritability.

Rare but serious (flag immediately)

The long-term cardiovascular debate

This is the most discussed point in 2024-2026.

The Zhang et al. 2024 study (JAMA Psychiatry) ^[7] followed 278,027 people with ADHD in Sweden over 14 years. Main results:

+4%

cardiovascular risk per additional year of stimulant treatment (cumulative)

• Use > 3-5 years: increased risk of CVD (cardiovascular disease) (adjusted Odds Ratio = 1.27).
• The excess risk is mostly for hypertension and arterial disease, not significantly for arrhythmias, heart attacks or strokes.
• Risk rises sharply in the first 3 years then stabilises.
• Effect more marked for stimulants than non-stimulants.

Important nuance: these are observational data. ADHD people already have a higher baseline cardiovascular risk (smoking, obesity, comorbidities). The absolute difference between treated and untreated remains modest for most.

Counterpoint: the Li et al. 2024 study (JAMA) ^[8] on 148,578 Swedish ADHD people shows that initiating an ADHD treatment is associated with lower all-cause mortality (HR = 0.79), especially from non-natural causes (suicide, accidents, overdoses). Untreated ADHD has its own mortality.

The French framework — what it concretely changes

Before starting

According to HAS ^[1] and NICE NG87 ^[10] , before starting any stimulant in adults, the clinician evaluates:

• Personal and family cardiovascular history (sudden death < 40, heart condition).
• Baseline blood pressure and heart rate.
• Weight, height (BMI).
• Psychiatric history (bipolar disorder, psychosis, active addictions).
• Substance use (alcohol, cannabis, cocaine).
• Pregnancy or pregnancy plans.

Systematic ECG: not recommended by NICE ^[10] unless there are risk factors or cardiac history. Many cautious French clinicians still request one — that’s acceptable.

Initial prescribing in France: what changed

The secure prescription (2025 rules)

New in January 2025 ^[3] :

• Secure prescription mandatory (tamper-proof paper).
• Maximum duration 28 days, non-renewable (you need a new prescription).
• Present to the pharmacist within 3 days of issue (beyond that, the remaining duration is cut accordingly).
• Designated pharmacy on the prescription (patient’s choice, noted by the prescriber).

Reimbursement

Reimbursed at 65% by the French public health insurance (Schedule I, controlled substance). Low remaining cost (a few euros/month in practice after top-up insurance).

The conversation with your psychiatrist

A few questions worth asking explicitly at initiation:

The titration phase

The approach recommended by HAS ^[1] and NICE ^[10] :

• Start with a low dose.
• Increase gradually in steps (typically weekly).
• Find the minimum effective dose — not the maximum dose.
• Evaluate response and side effects at 4-6 weeks.

This page won’t give you a precise dose — that’s an individual clinical decision. But you can know that a well-run titration often takes 6-12 weeks before the picture is clear.

What counts as “effective”

Not just “I feel good”. In clinical terms:

• Reduction of ADHD symptoms (scales like ASRS, WRAADDS, ADHD-RS-IV).
• Functional impact (work, relationships, day-to-day).
• Subjective experience (quality of life, sleep, mood).
• Absence of disqualifying side effects.

A treatment that reduces symptoms by 30% but generates major anxiety = not a good treatment. Subjective experience counts.

Shortages and supply disruption — prepare for the possibility

France has recurring supply tensions on Ritaline LP, Quasym LP and generics since 2023. See the dedicated shortages page for details.

In practice:

• Don’t take 6 boxes at the pharmacy “just in case” (it’s illegal and counter-productive).
• Ask your psychiatrist for a plan B (which molecule/formulation to switch to if a shortage hits).
• Subscribe to HyperSupers and ANSM updates to follow the situation.

If you’re considering this treatment

You don’t have to decide alone. The right framework:

• Formal ADHD diagnosis in place.
• Cardiovascular and psychiatric baseline assessment.
• Honest conversation with a psychiatrist trained in adult ADHD.
• A trusted person informed to track behavioural changes (an external observer is useful).
• Planned follow-up (not just the prescription and goodbye).

I thought it would transform me. Actually it gave me back the ability to do boring stuff without my brain going up in smoke. That’s the thing. Not a superpower. Just being able to do the dishes without it being a drama.

Signals for emergency consultation

Takeaways

Go further

• Lisdexamfetamine (Elvanse / XURTA) — the other option
• Atomoxetine (Strattera) — when stimulants don’t fit
• Methylphenidate shortages in France — what to do
• Managing side effects — practical guide
• The diagnostic pathway